---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-024422"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2022-08-30T23:59:59+00:00"
generated_at: "2026-06-23T19:12:31.968593+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma settles $6.5M Cytovance debt with stock and cash; aims for IND filings by Mar/Jun 2023

## Summary
- Issued 1,222,281 shares to Cytovance to settle $3.25M of invoices; will pay another $3.25M in cash over three months.
- Future invoices paid 50% cash and 50% in common stock at closing price; materials invoices all cash.
- Cytovance to facilitate GTB-3650 IND by March 31, 2023 and GTB-5550 IND by June 30, 2023, subject to conditions.
- Cytovance ownership capped at 4.9% of outstanding; daily resale limited to 50k shares or 1/3 of avg weekly volume.
- Parties release each other from claims arising prior to agreement effectiveness.

## SEC filing metadata
- accession: 0001493152-22-024422
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2022-08-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315222024422/0001493152-22-024422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315222024422/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-024422
- JSON: https://secwatch.observer/filing/0001493152-22-024422.json
- Plain text: https://secwatch.observer/filing/0001493152-22-024422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.